Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Product Overview:
Adiponectin is a pleiotropic adipokine and homolog of the complement 1q (C1q) family encoded by ADIPOQ in humans.{52597} It is composed of an N-terminal signal sequence, a hypervariable region, a collagenous domain, and a C-terminal C1q-like globular domain. It is produced in adipocytes, where the approximately 27 kDa monomeric protein is post-translationally modified to induce formation of trimer, hexamer, and high molecular weight (HMW) adiponectin containing 12 to 18 monomers that circulate in serum. These adiponectin multimers have distinct biological activities and do not interconvert once present in the circulation. Peroxisome proliferator-activated receptor ? (PPAR?) is the major positive regulator of ADIPOQ expression but expression is also regulated by forkhead box protein O1 (FOXO1) and sterol regulatory element binding protein 1c (SREBP1c). Plasma levels of adiponectin are decreased in ob/ob mice and mice with diet-induced obesity that have insulin resistance, and exogenous administration of adiponectin improves insulin sensitivity in these mice by increasing ?-oxidation in the skeletal muscle and reducing hepatic and musculoskeletal triglyceride content. Chronic administration of adiponectin reduces hyperglycemia, hyperinsulinemia, and body weight in a mouse model of high-fat diet-induced obesity. High plasma levels of adiponectin are associated with coronary heart disease in diabetic women.{52598} Plasma levels of adiponectin are positively correlated with disease severity in patients with chronic kidney disease.{52599} Cayman’s Adiponectin (human, recombinant) protein is a disulfide-linked homodimer. The reduced monomer, comprised of adiponectin (amino acids 19-244) fused to human IgG1 Fc at its C-terminus, consists of 467 amino acids, has a calculated molecular weight of 51.6 kDa, and a predicted N-terminus of Glu19 after signal peptide cleavage.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.